The Babak Lab shared a post on LinkedIn, about a recent article by Fangmian Wei et al. published in Coordination Chemistry Reviews:
“Metallodrugs in Cancer Chemoimmunotherapy
A new review published in Coordination Chemistry Reviews explores how metallodrugs – metal-based complexes traditionally used in chemotherapy are gaining traction as tools for chemoimmunotherapy, combining direct tumor cytotoxicity with immune activation.
Key Focus
The article reviews strategies to enhance chemoimmunogenicity through metallodrugs, particularly by triggering immunogenic cell death (ICD) – a process that transforms dying cancer cells into an “in situ vaccine”.
Key Insights
- Metallodrugs can modulate immune responses by targeting organelles (e.g., ER, mitochondria)
- ICD-inducing agents may help prevent tumor metastasis and recurrence
- Novel design strategies include site-controlled toxicity, regulated cell death, and combination therapy with immune checkpoint inhibitors
Conclusion
Metallodrugs are no longer just cytotoxic agents – they’re emerging as dual-purpose molecules that kill tumors and reprogram the immune system. This dual action holds promise for more effective and lasting cancer therapies.
Image generated using Sora by OpenAI.”
Title: Recent advances in the development of metallodrugs for cancer chemoimmunotherapy
Authors: Fangmian Wei, Jinzhe Liang, Xing-Can Shen, Yihang Pan, Yulong He, Hui Chao
Read the Full Article on Coordination Chemistry Reviews
Maria (Masha) Babak, Head of The Babak Lab and Assistant Professor at City University of Hong Kong, shared this post, adding:
“The future of chemoimmunotherapy might be metallic!”
More posts featuring Maria (Masha) Babak